文献速递湿疹皮炎与荨麻疹

特应性皮炎局部治疗:聚焦吡美莫司

Topical therapy of atopic dermatitis with a focus on pimecrolimus.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-05-02

特应性皮炎是慢性复发性炎症性皮肤病,基础治疗为润肤剂和避免触发因素,不足时外用糖皮质激素为一线。因激素恐惧和副作用导致依从性低,外用钙调神经磷酸酶抑制剂如吡美莫司被证实抗炎效果与低至中效激素相似,且不引起皮肤萎缩、具有激素节省作用且安全性良好。

要点

  • 吡美莫司抗炎效果与低至中效外用糖皮质激素相似。
  • 吡美莫司不引起皮肤萎缩,具有激素节省作用,安全性良好。
  • 吡美莫司乳膏耐受性好,适合儿童和敏感皮肤区域使用。

核心结论

  • 吡美莫司乳膏抗炎效果与低至中效外用糖皮质激素相似,可减轻瘙痒、改善生活质量。
  • 吡美莫司不引起皮肤萎缩,具有激素节省作用,安全性良好,无恶性肿瘤或皮肤感染风险增加的证据。

研究设计与样本

  • 综述总结了多项长期和短期随机对照研究及日常实践研究。

主要发现

  • 吡美莫司乳膏抗炎效果与低至中效外用糖皮质激素相似。
  • 吡美莫司可减轻瘙痒并改善患者生活质量。
  • 吡美莫司不引起皮肤萎缩,具有激素节省作用,安全性良好。
  • 无证据表明吡美莫司增加恶性肿瘤或皮肤感染风险。
  • 吡美莫司乳膏耐受性好,促进患者依从性,许多医生将其作为儿童和敏感皮肤区域的首选治疗。

关键数值与推荐

  • 基础治疗包括使用润肤剂和避免触发因素。
  • 当基础治疗不足时,外用糖皮质激素是一线治疗。
  • 外用钙调神经磷酸酶抑制剂如吡美莫司可作为儿童和敏感皮肤区域的首选治疗。

临床怎么用

  • 对于儿童和敏感皮肤区域,可考虑使用吡美莫司乳膏作为首选局部治疗。
  • 因激素恐惧或外用糖皮质激素副作用导致依从性低时,可选用吡美莫司。
  • 吡美莫司可作为激素节省剂使用。

局限性

  • 原文未明确报告综述的检索范围、纳入研究数量或具体样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a chronic and relapsing, inflammatory skin disease characterized by impaired skin barrier function and immune system dysregulation that results in dryness, skin microbiome dysbiosis and intense pruritus. It is highly heterogeneous, and its management is demanding. Patients with AD are at greater risk of comorbidities such as attention-deficit hyperactivity disorder as well as other atopic diseases. Early-onset AD cases typically improve or resolve in late childhood; however, it is proposed that the prevalence of persistent or adult-onset AD is higher than previously thought. Basic therapy consists of emollient application and trigger avoidance, and when insufficient, topical corticosteroids (TCS) are the first-line treatment. However, corticophobia/steroid aversion and TCS side-effects, particularly on sensitive skin areas, lead to low compliance and insufficient disease control. Several long- and short-term randomized controlled and daily practice studies have demonstrated that topical calcineurin inhibitors, such as pimecrolimus, have similar anti-inflammatory effects to low-to-medium strength TCS, reduce pruritus and improve the quality of life of patients. In addition, pimecrolimus does not cause skin atrophy, is steroid-sparing and has a good safety profile, with no evidence for an increased risk of malignancies or skin infections. In general, pimecrolimus cream is well-accepted and well-tolerated, encouraging patient adherence and leading to its use by many physicians as a preferred therapy for children and sensitive skin areas.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Luger T, Paller AS, Irvine AD, et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol. 2021. PMID: 33834524. doi:10.1111/jdv.17272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。